8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


       Date of report (Date of earliest event reported): February 12, 2002


                         AMERICAN BIO MEDICA CORPORATION
              ----------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

              New York                    0-28666              14-1702188
  -------------------------------      ------------       ----------------------
  (State or Other Jurisdiction of      (Commission           (IRS Employer
          Incorporation)               File Number)       Identification Number)



           122 Smith Road, Kinderhook, NY                  12106
           ---------------------------------------------------------
           (Address of Principal Executive Offices)      (Zip Code)

       Registrant's telephone number, including area code: (800) 227-1243











ITEM 5. OTHER EVENTS

         On February 12, 2002, D. Joseph Gursuk was elected to the Registrant's
Board of Directors. Mr. Gursuk is the executive vice president and chief
financial officer of MapInfo Corporation, a publicly traded, software technology
company based in Troy, New York. Mr. Gursuk was also elected to the Registrant's
Audit, Compensation and Option Committees.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.

    (c) Exhibits.

        The following exhibits are filed with this report on Form 8-K:

        99.1  American Bio Medica Corporation press release dated
              February 13, 2002






                                       2




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                              AMERICAN BIO MEDICA CORPORATION
                                              (Registrant)


Dated:  February 13, 2002                     By: /s/ Keith E. Palmer
                                                  ------------------------------
                                                  Keith E. Palmer
                                                  Chief Financial Officer









                                       3





                                  Exhibit Index


Exhibit No.                  Description                                Page No.
- -----------                  -----------                                --------
99.1              American Bio Medica Corporation press                    5
                  release dated February 13, 2002










                                       4

EX-99

                                                                    Exhibit 99.1



FOR IMMEDIATE RELEASE:

                ABMC APPOINTS JOSEPH GERSUK TO BOARD OF DIRECTORS
       Chief Financial Officer and Treasurer of MapInfo Corporation Brings
            Extensive Finance and Technology Background to ABMC Board

KINDERHOOK, NY, February 13, 2002 - American Bio Medica Corporation (NASDAQ:
ABMC) today announced that Joseph Gersuk has been appointed to its board of
directors. Gersuk, who is the executive vice president and chief financial
officer for global software technology leader MapInfo Corporation (NASDAQ:
MAPS), was elected at a meeting of the ABMC board yesterday.

ABMC board chairman and chief executive officer Gerald Moore said that Gersuk's
appointment would bring to ABMC the insights of a results-driven senior
corporate officer with a broad financial background in international and
domestic technology businesses.

"We are very fortunate to have Joe Gersuk on our board of directors, as he
brings 15 years of CFO experience to the board, with expertise in financial
operations, capital markets, and building successful relationships with Wall
Street," said Moore. "The finance end of ABMC's business is a strategic priority
for us as we expand our domestic and international sales effort, and we can only
benefit from having Joe Gersuk as a director."

"I am delighted to join ABMC's board of directors and look forward to working
with Gerald Moore and his executive team to accelerate the company's growth. I
recently acquired an equity position in ABMC and I plan to increase it in the
future."

Gersuk has served as CFO and treasurer for MapInfo since joining the Troy, New
York-based company in 1994. Prior to that, he was vice president, CFO, and
director of Dataease Sapphire International Inc., a $33 million software
publisher based in Trumbull, Connecticut. He also serves as trustee and
treasurer of The Albany Academy for Girls.

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets inexpensive,
accurate, on-site drugs-of-abuse diagnostic kits, sprays and support services
worldwide. The company's global distributors target the workplace, physicians,
corrections, clinical, and educational markets. ABMC's Rapid Drug Screen(R) and
OralStat6(TM) test for the presence or absence of drugs of abuse in urine and
saliva, respectively, while its Drug Detector(TM) identifies minute traces of
illegal drugs on surfaces. ABMC was recently listed among the top ten
biotechnology companies on the Deloitte & Touche 2001 Technology Fast 500, a
ranking of the fastest growing companies in North America.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risk and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, intellectual property rights and other risks
detailed from time to time in the Company's periodic reports filed with the
Securities and Exchange Commission.

                                      # # #

                                       5